Veracyte, Inc.
VCYT
Rang in Aktien
#4356
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aktienkurs
$44.68
Marktkapitalisierung
$3.59B
Veränderung (1 Tag)
2.01%
Veränderung (1 Jahr)
21.91%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategorie
Healthcare
P/S-Verhältnis für Veracyte, Inc. (VCYT)
P/S-Verhältnis zum October 2026 TTM: 6.22
Laut den neuesten Finanzberichten und dem Aktienkurs von Veracyte, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 6.22. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 5.54.
P/S-Verlauf für Veracyte, Inc. von 2011 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 6.22 | -8.32% |
| 2024 | 6.79 | 22.75% |
| 2023 | 5.54 | -3.33% |
| 2022 | 5.73 | -55.07% |
| 2021 | 12.74 | -42.55% |
| 2020 | 22.18 | 107.23% |
| 2019 | 10.70 | 111.43% |
| 2018 | 5.06 | 64.40% |
| 2017 | 3.08 | -10.20% |
| 2016 | 3.43 | -9.14% |
| 2015 | 3.77 | -31.06% |
| 2014 | 5.47 | 98.64% |
| 2013 | 2.76 | -82.96% |
| 2012 | 16.18 | -77.25% |
| 2011 | 71.11 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 5.37 | -13.70% |
US
|
|
| 6.29 | 1.08% |
US
|
|
| 21.02 | 237.66% |
US
|
|
| - | - |
CN
|
|
| 6.67 | 7.09% |
US
|
